News

Serum levels of E-selectin (sE-selectin) and soluble interleukin-2 receptor (sIL-2R) are potential prognostic markers of progression and severity in localized scleroderma, according to a recent study. The study, “The correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized scleroderma” was published…

Systemic sclerosis (SSc) patients showed reduced skin thickness and improved lung function after a hematopoietic stem cell transplant (HSCT) using blood progenitor cells positive for the CD34 marker, a study reports. This finding suggests that CD34-selected autologous HSCT may have additional clinical benefits over conventional autologous HSCT. The study,…

Certain clinical characteristics that researchers suggest could be potentially useful indicators of interstitial lung disease in systemic sclerosis (SSc) patients were recently identified in a study. Findings indicated that longer disease duration, positive anti-Scl70 antibody titers, higher white blood cell and platelet counts, greater erythrocyte sedimentation rate (ESR) levels,…

Treatment with rituximab may help improve the clinical symptoms of calcinosis — the formation of calcium deposits in the skin and muscle — of systemic sclerosis (SSc) patients, a small study suggests. The study, “Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series…

Among patients with systemic sclerosis (SSc), those who have pulmonary arterial hypertension (PAH) have a distinct pattern of active and silent genes compared with those who develop interstitial lung disease (ILD), a preliminary…

While there are significant differences in how patients with juvenile localized scleroderma (JLS) are assessed and screened in the United Kingdom, treatment approaches are consistent, a study has found. The study, “Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management,” was…

A new blood test measures autoantibodies called anti-vinculin, which have been found to be higher in scleroderma patients and have also been associated with gastrointestinal complications and pulmonary hypertension. The test, called sclero-smart, was developed through a partnership with the Medically Associated Science and Technology (MAST) program at…

Treatment with plant-derived salvianolic acid B (SAB) reduced skin fibrosis in a mouse model of scleroderma. The findings suggest that SAB may be an effective treatment for people with scleroderma. The research, “Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis,” was published in the…

A Phase 2a clinical trial will test the investigational therapy GLPG1690 in patients with diffuse cutaneous scleroderma. The double-blind, placebo-controlled Phase 2a study, called NOVESA (NCT03798366), will evaluate the efficacy, safety, and pharmacological profile of Galapagos’ GLPG1690. It is set to enroll 30 participants with diffuse cutaneous…

IGFBP-5, a protein that appears to be involved in the early stages of fibrosis, may be a potential therapy for lung fibrosis, new preclinical research done at the Medical University of South Carolina (MUSC) found. Using human lung fibroblasts and lung…